ClinicalTrials.gg
CompletedNCT04632927AgAINUpdated Oct 16, 2025Results posted

Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

A Phase 3 interventional study of Secukinumab and Ustekinumab in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.

Enrollment
16th of 26
119 · median 231
Started
2020
with 3 others
Phase 3
16 of 26
1 open now
Registered
22nd of 26
by date
Lead sponsor
17 of 26
Novartis Pharmaceuticals

Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 16th largest by enrollment, is one of 4 that started in 2020, is one of 16 in phase 3, and was the 22nd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing secukinumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic Arthritis
  • Psoriasis Arthropathica
  • Psoriatic Arthropathy
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of PsA as classified by CASPAR criteria for at least 6 months before randomization.
  • Active PsA at baseline defined as ≥ 3 tender joints out of 68 and ≥ 3 swollen joints out of 66 (dactylitis of a digit counts as one joint each).
  • Inadequate response or intolerance to previous or current treatment with at least one TNFα inhibitor
  • Inadequate response or intolerance to conventional disease modifying anti-rheumatic drugs (cDMARDs)
  • Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥ 2 cm diameter and/or nail changes consistent with psoriasis and/or documented history of plaque psoriasis.
  • Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies negative at screening.

Key Exclusion Criteria:

  • Pregnant or nursing women,
  • Previous exposure to secukinumab, ustekinumab or any other biologic drug directly targeting IL-17, IL-17 receptor, IL-12 or IL-23.
  • Patients for whom the use of secukinumab or ustekinumab is .
  • Use of any other drug. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 or investigational agents
  • Evidence of ongoing infectious or malignant process
  • Subjects receiving high potency opioid analgesics
  • Ongoing use of prohibited psoriasis treatments/medications

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Secukinumab

    AIN457

    Biological: Secukinumab · Biological: Ustekinumab

  • Experimental
    Ustekinumab

    Biological: Secukinumab · Biological: Ustekinumab

Interventions

  • BiologicalSecukinumab

    Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

    Also known as: AIN457

  • BiologicalUstekinumab

    Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28

    The disability assessment component of the HAQ evaluated a subject's level of functional ability through 20 questions grouped into 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item began with the prompt "Over the past week, are you able to…" and is scored on a 4-point scale: 0 (no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The overall score was calculated by averaging the scores across all answered domains, resulting in a total score ranging from 0 (no disability) to 3 (severe disability). A HAQ-DI response was defined as an improvement of ≥0.35 points from baseline at Week 28. Missing values were imputed as non-responders

    Time frame: Baseline, Week 28

Secondary outcomes

  1. Number of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 28

    The Psoriasis Area and Severity Index (PASI) was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved at least a 90% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.

    Time frame: Baseline, Week 28

  2. Change From Baseline in Patient's Assessment of Pain on VAS at Week 28

    The patient's level of pain was evaluated using a horizontal Visual Analogue Scale (VAS), on which individuals marked their pain intensity with a vertical tick. The scale ranged from 0 mm (indicating "no pain") to 100 mm (indicating "unbearable pain"). The change in the patient's pain assessment on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 28

  3. Change From Baseline in Tender Joint Count (TJC) 68 at Week 28

    Tender joint count (TJC) 68 was a method of assessing joint inflammation. Number of tender joints was determined by examining 68 joints and identifying the joints that were painful under pressure or to passive motion. The 68 joints assessed for tenderness included the 2 temporomandibular, 2 sternoclavicular, 2 acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 2 hips, 2 knees, 2 talo¬tibial, 2 mid-tarsal, 10 metatarsophalangeal, and 10 proximal interphalangeal joints of the feet. The change from baseline in TJC68 at Week 28 was assessed. A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 28

  4. Change From Baseline in Swollen Joint Count (SJC) 66 at Week 28

    Swollen Joint Count (SJC) 66 was a method of assessing joint inflammation. The number of swollen joints was determined by examining 66 joints and identifying those with visible or palpable swelling suggestive of synovitis. The 66 joints assessed for swelling included the 2 sternoclavicular, 2 acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 2 knees, 2 talotibial, 2 mid-tarsal, 10 metatarsophalangeal, and 10 proximal interphalangeal joints of the feet. The change from baseline in SJC66 at Week 28 was assessed. A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 28

  5. Number of Patients Achieving PASI 100 at Week 28

    The PASI was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved 100% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.

    Time frame: Bseline, Week 28

  6. Number of Patients Achieving PASI 75 at Week 28

    The Psoriasis Area and Severity Index (PASI) was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved at least a 75% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.

    Time frame: Baseline, Week 28

  7. Change From Baseline in Patient's Global Assessment of Disease Activity on VAS

    The patient's global assessment of disease activity was performed using a 100 mm (VAS) ranging from 0 (='very good') to 100 (='very poor') after the question 'Considering all the ways Psoriatic Arthritis affects you, please indicate with a vertical mark through the horizontal line how well you are today'. The change in the patient's global assessment on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 28

  8. Change From Baseline in Patient's Global Assessment of Psoriasis and Arthritis Disease Activity on VAS

    The patient's assessment of psoriasis and arthritis was performed using a 100 mm VAS ranging from 0 (='Excellent') to 100 (='Poor') after the question 'Considering all the ways PSORIASIS and ARTHRITIS affects you, please indicate with a vertical mark through the horizontal line how well you are doing over the past week' The change in the patient's global assessment of psoriasis and arthritis disease activity on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 28

  9. Number of Patients Achieving Minimal Disease Activity (MDA) at Week 28

    MDA was a composite endpoint used to assess low disease activity in patients with psoriatic arthritis and psoriasis. A patient was considered to have achieved MDA if they met at least 5 of the following 7 criteria: * TJC (0-68)≤1 * SJC (0-66 joints)≤1 * PASI ≤1 \[the total score ranged from 0 (no disease) to 72 (maximal disease)\] or body surface area≤3% * Patient's pain VAS ≤ 15 mm on a 100 mm scale, where 0 ="no pain" and 100= "pain as severe as can be imagined" * Patient's global assessment of disease activity (PtGA) ≤ 20 mm on a 100 mm scale, where 0 represented the lowest level of disease activity and 100 the highest * HAQ-DI ≤ 0.5, where 0 represented no difficulty and 3 represented inability to perform activities * Enthesitis count ≤ 1, based on the Leeds Enthesitis Index, where 0 indicated no tenderness and 6 indicated tenderness at all assessed tendon insertions The number of participants achieving MDA at Week 28 was assessed. Missing values were imputed as non-responders.

    Time frame: Week 28

  10. Change From Baseline in the Leeds Enthesitis Index (LEI)

    The LEI was a validated enthesitis index that used six sites to evaluate enthesitis: the left and right lateral epicondyles of the humerus, the left and right proximal Achilles tendon insertions, and the left and right medial femoral condyles.Each site was scored as 0 (non-tender) or 1 (tender), resulting in a total score ranging from 0 to 6. A higher score reflected a greater burden of enthesitis. The change in the LEI score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in enthesitis severity

    Time frame: Baseline, Week 28

  11. Change From Baseline in the Leeds Dactylitis Index (LDI)

    The LDI was used to quantitatively assess dactylitis by measuring the circumference of affected digits and their corresponding control digits, along with the tenderness of each affected digit. Digits were classified as dactylitic if there was a ≥10% difference in circumference compared to the contralateral digit. When both digits were affected or a contralateral control was unavailable, a standardized reference range was applied. For each dactylitic digit, the ratio of the affected to control circumference was multiplied by a binary tenderness score (1 = tender, 0 = non-tender). The resulting values were summed across all affected digits to calculate the total LDI score. Scores ranged from 0 to 20, with higher scores indicating more severe or widespread dactylitis. The change in the LDI score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in dactylitis severity.

    Time frame: Baseline, Week 28

  12. Change From Baseline in Psoriatic Arthritis Quality of Life (PsAQoL)

    The PsAQoL questionnaire was used to assess the impact of psoriatic arthritis on patients' quality of life. The PsAQoL is a validated, disease-specific, self-administered instrument consisting of 20 items with binary response options ("true" or "not true"). Items covered physical, emotional, and social domains, including fatigue, independence, and interpersonal relationships. The total score ranged from 0 to 20, with higher scores indicating greater impairment in quality of life. The change in the PsAQoL score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in health-related quality of life.

    Time frame: Baseline, Week 28

  13. Percentage of Participants Achieving a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Response at Week 28

    The FACIT-Fatigue Scale was used to assess fatigue and its impact on daily functioning over the previous 7 days. The instrument consisted of 13 self-administered items, each scored on a 5-point Likert scale ranging from 0 ("Not at all") to 4 ("Very much"). The total score ranged from 0 to 52, with higher scores indicating less fatigue and better functioning. Response was achieved if the score had improved by at least 4 points from baseline. Missing values were imputed as non-responders

    Time frame: Baseline, Week 28

  14. Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Response at Week 28

    The DLQI was used to evaluate the impact of dermatological conditions on patients' quality of life over the previous 7 days. It consisted of 10 self-administered items covering symptoms, daily activities, leisure, work/school, personal relationships, and treatment burden. Each item was scored from 0 ("Not at all") to 3 ("Very much"), with a total score ranging from 0 to 30. Higher scores indicated greater impairment. Response was achieved if the absolute score was either 0 or 1. Missing values were imputed as non-responders.

    Time frame: Week 28

07

Results

Posted Oct 16, 2025

Participant flow

Patients were randomized in 28 study sites across Germany

Participant flow — Overall Study
MilestoneSecukinumabUstekinumab
Started5663
Completed5653
Not completed010
Withdrew: Adverse event01
Withdrew: Lack of efficacy04
Withdrew: Loss of efficacy01
Withdrew: Non-compliance with study drug01
Withdrew: Physician decision01
Withdrew: Subject decision01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryProportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28

The disability assessment component of the HAQ evaluated a subject's level of functional ability through 20 questions grouped into 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item began with the prompt "Over the past week, are you able to…" and is scored on a 4-point scale: 0 (no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The overall score was calculated by averaging the scores across all answered domains, resulting in a total score ranging from 0 (no disability) to 3 (severe disability). A HAQ-DI response was defined as an improvement of ≥0.35 points from baseline at Week 28. Missing values were imputed as non-responders

Time frame:
Baseline, Week 28
Reported as:
Count of participants · Participants
Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28
ParticipantsSecukinumabUstekinumab
Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 283217
Statistical analysis
  • Secukinumab vs Ustekinumab · Regression, Logistic · p = 0.002 · Odds ratio (or): 3.647 · 95% CI 1.601 to 8.311The OR was calculated using a logistic regression model with treatment group, baseline HAQ-DI and strata (body weight) as independent variables
SecondaryNumber of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 28

The Psoriasis Area and Severity Index (PASI) was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved at least a 90% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.

Time frame:
Baseline, Week 28
Reported as:
Count of participants · Participants
Number of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 28
ParticipantsSecukinumabUstekinumab
Number of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 282725
SecondaryChange From Baseline in Patient's Assessment of Pain on VAS at Week 28

The patient's level of pain was evaluated using a horizontal Visual Analogue Scale (VAS), on which individuals marked their pain intensity with a vertical tick. The scale ranged from 0 mm (indicating "no pain") to 100 mm (indicating "unbearable pain"). The change in the patient's pain assessment on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a Scale
Change From Baseline in Patient's Assessment of Pain on VAS at Week 28
Score on a ScaleSecukinumabUstekinumab
Change From Baseline in Patient's Assessment of Pain on VAS at Week 28-27.1 ± 25.8-16.4 ± 24.2
SecondaryChange From Baseline in Tender Joint Count (TJC) 68 at Week 28

Tender joint count (TJC) 68 was a method of assessing joint inflammation. Number of tender joints was determined by examining 68 joints and identifying the joints that were painful under pressure or to passive motion. The 68 joints assessed for tenderness included the 2 temporomandibular, 2 sternoclavicular, 2 acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 2 hips, 2 knees, 2 talo¬tibial, 2 mid-tarsal, 10 metatarsophalangeal, and 10 proximal interphalangeal joints of the feet. The change from baseline in TJC68 at Week 28 was assessed. A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a Scale
Change From Baseline in Tender Joint Count (TJC) 68 at Week 28
Score on a ScaleSecukinumabUstekinumab
Change From Baseline in Tender Joint Count (TJC) 68 at Week 28-9.6 ± 11.9-7.6 ± 10.7
SecondaryChange From Baseline in Swollen Joint Count (SJC) 66 at Week 28

Swollen Joint Count (SJC) 66 was a method of assessing joint inflammation. The number of swollen joints was determined by examining 66 joints and identifying those with visible or palpable swelling suggestive of synovitis. The 66 joints assessed for swelling included the 2 sternoclavicular, 2 acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 2 knees, 2 talotibial, 2 mid-tarsal, 10 metatarsophalangeal, and 10 proximal interphalangeal joints of the feet. The change from baseline in SJC66 at Week 28 was assessed. A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a Scale
Change From Baseline in Swollen Joint Count (SJC) 66 at Week 28
Score on a ScaleSecukinumabUstekinumab
Change From Baseline in Swollen Joint Count (SJC) 66 at Week 28-6.8 ± 6.3-5.3 ± 5.2
SecondaryNumber of Patients Achieving PASI 100 at Week 28

The PASI was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved 100% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.

Time frame:
Bseline, Week 28
Reported as:
Count of participants · Participants
Number of Patients Achieving PASI 100 at Week 28
ParticipantsSecukinumabUstekinumab
Number of Patients Achieving PASI 100 at Week 282117
SecondaryNumber of Patients Achieving PASI 75 at Week 28

The Psoriasis Area and Severity Index (PASI) was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved at least a 75% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.

Time frame:
Baseline, Week 28
Reported as:
Count of participants · Participants
Number of Patients Achieving PASI 75 at Week 28
ParticipantsSecukinumabUstekinumab
Number of Patients Achieving PASI 75 at Week 283429
SecondaryChange From Baseline in Patient's Global Assessment of Disease Activity on VAS

The patient's global assessment of disease activity was performed using a 100 mm (VAS) ranging from 0 (='very good') to 100 (='very poor') after the question 'Considering all the ways Psoriatic Arthritis affects you, please indicate with a vertical mark through the horizontal line how well you are today'. The change in the patient's global assessment on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a Scale
Change From Baseline in Patient's Global Assessment of Disease Activity on VAS
Score on a ScaleSecukinumabUstekinumab
Change From Baseline in Patient's Global Assessment of Disease Activity on VAS-26.0 ± 21.8-15.5 ± 23.1
SecondaryChange From Baseline in Patient's Global Assessment of Psoriasis and Arthritis Disease Activity on VAS

The patient's assessment of psoriasis and arthritis was performed using a 100 mm VAS ranging from 0 (='Excellent') to 100 (='Poor') after the question 'Considering all the ways PSORIASIS and ARTHRITIS affects you, please indicate with a vertical mark through the horizontal line how well you are doing over the past week' The change in the patient's global assessment of psoriasis and arthritis disease activity on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a Scale
Change From Baseline in Patient's Global Assessment of Psoriasis and Arthritis Disease Activity on VAS
Score on a ScaleSecukinumabUstekinumab
Change From Baseline in Patient's Global Assessment of Psoriasis and Arthritis Disease Activity on VAS-28.1 ± 23.6-16.2 ± 24.8
SecondaryNumber of Patients Achieving Minimal Disease Activity (MDA) at Week 28

MDA was a composite endpoint used to assess low disease activity in patients with psoriatic arthritis and psoriasis. A patient was considered to have achieved MDA if they met at least 5 of the following 7 criteria: * TJC (0-68)≤1 * SJC (0-66 joints)≤1 * PASI ≤1 \[the total score ranged from 0 (no disease) to 72 (maximal disease)\] or body surface area≤3% * Patient's pain VAS ≤ 15 mm on a 100 mm scale, where 0 ="no pain" and 100= "pain as severe as can be imagined" * Patient's global assessment of disease activity (PtGA) ≤ 20 mm on a 100 mm scale, where 0 represented the lowest level of disease activity and 100 the highest * HAQ-DI ≤ 0.5, where 0 represented no difficulty and 3 represented inability to perform activities * Enthesitis count ≤ 1, based on the Leeds Enthesitis Index, where 0 indicated no tenderness and 6 indicated tenderness at all assessed tendon insertions The number of participants achieving MDA at Week 28 was assessed. Missing values were imputed as non-responders.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Patients Achieving Minimal Disease Activity (MDA) at Week 28
ParticipantsSecukinumabUstekinumab
Number of Patients Achieving Minimal Disease Activity (MDA) at Week 282014
SecondaryChange From Baseline in the Leeds Enthesitis Index (LEI)

The LEI was a validated enthesitis index that used six sites to evaluate enthesitis: the left and right lateral epicondyles of the humerus, the left and right proximal Achilles tendon insertions, and the left and right medial femoral condyles.Each site was scored as 0 (non-tender) or 1 (tender), resulting in a total score ranging from 0 to 6. A higher score reflected a greater burden of enthesitis. The change in the LEI score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in enthesitis severity

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a Scale
Change From Baseline in the Leeds Enthesitis Index (LEI)
Score on a ScaleSecukinumabUstekinumab
Change From Baseline in the Leeds Enthesitis Index (LEI)-0.9 ± 1.8-0.5 ± 1.5
SecondaryChange From Baseline in the Leeds Dactylitis Index (LDI)

The LDI was used to quantitatively assess dactylitis by measuring the circumference of affected digits and their corresponding control digits, along with the tenderness of each affected digit. Digits were classified as dactylitic if there was a ≥10% difference in circumference compared to the contralateral digit. When both digits were affected or a contralateral control was unavailable, a standardized reference range was applied. For each dactylitic digit, the ratio of the affected to control circumference was multiplied by a binary tenderness score (1 = tender, 0 = non-tender). The resulting values were summed across all affected digits to calculate the total LDI score. Scores ranged from 0 to 20, with higher scores indicating more severe or widespread dactylitis. The change in the LDI score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in dactylitis severity.

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a Scale
Change From Baseline in the Leeds Dactylitis Index (LDI)
Score on a ScaleSecukinumabUstekinumab
Change From Baseline in the Leeds Dactylitis Index (LDI)-9.7 ± 27.2-7.2 ± 25.9
SecondaryChange From Baseline in Psoriatic Arthritis Quality of Life (PsAQoL)

The PsAQoL questionnaire was used to assess the impact of psoriatic arthritis on patients' quality of life. The PsAQoL is a validated, disease-specific, self-administered instrument consisting of 20 items with binary response options ("true" or "not true"). Items covered physical, emotional, and social domains, including fatigue, independence, and interpersonal relationships. The total score ranged from 0 to 20, with higher scores indicating greater impairment in quality of life. The change in the PsAQoL score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in health-related quality of life.

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a Scale
Change From Baseline in Psoriatic Arthritis Quality of Life (PsAQoL)
Score on a ScaleSecukinumabUstekinumab
Change From Baseline in Psoriatic Arthritis Quality of Life (PsAQoL)-2.5 ± 5.1-2.0 ± 5.4
SecondaryPercentage of Participants Achieving a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Response at Week 28

The FACIT-Fatigue Scale was used to assess fatigue and its impact on daily functioning over the previous 7 days. The instrument consisted of 13 self-administered items, each scored on a 5-point Likert scale ranging from 0 ("Not at all") to 4 ("Very much"). The total score ranged from 0 to 52, with higher scores indicating less fatigue and better functioning. Response was achieved if the score had improved by at least 4 points from baseline. Missing values were imputed as non-responders

Time frame:
Baseline, Week 28
Reported as:
Count of participants · Participants
Percentage of Participants Achieving a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Response at Week 28
ParticipantsSecukinumabUstekinumab
Percentage of Participants Achieving a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Response at Week 284032
SecondaryPercentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Response at Week 28

The DLQI was used to evaluate the impact of dermatological conditions on patients' quality of life over the previous 7 days. It consisted of 10 self-administered items covering symptoms, daily activities, leisure, work/school, personal relationships, and treatment burden. Each item was scored from 0 ("Not at all") to 3 ("Very much"), with a total score ranging from 0 to 30. Higher scores indicated greater impairment. Response was achieved if the absolute score was either 0 or 1. Missing values were imputed as non-responders.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Response at Week 28
ParticipantsSecukinumabUstekinumab
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Response at Week 283032

Adverse events

Collected over From start of treatment to end of study, assessed up to approximately 36 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab- On-Treatment0/56 (0%)3/56 (5.4%)27/56 (48.2%)
Ustekinumab - On-Treatment0/63 (0%)1/63 (1.6%)31/63 (49.2%)
Secukinumab - Entire Study0/56 (0%)4/56 (7.1%)31/56 (55.4%)
Ustekinumab - Entire Study0/63 (0%)2/63 (3.2%)32/63 (50.8%)
Most frequent serious events
Most frequent serious events
EventSecukinumab- On-TreatmentUstekinumab - On-TreatmentSecukinumab - Entire StudyUstekinumab - Entire Study
Oesophageal candidiasisInfections and infestations0/560/631/560/63
PneumoniaInfections and infestations1/560/631/560/63
Urinary tract infectionInfections and infestations1/560/631/560/63
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/560/631/560/63
Vertebrobasilar strokeNervous system disorders0/560/630/561/63
PsoriasisSkin and subcutaneous tissue disorders0/561/630/561/63
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSecukinumab- On-TreatmentUstekinumab - On-TreatmentSecukinumab - Entire StudyUstekinumab - Entire Study
NasopharyngitisInfections and infestations5/569/637/569/63
COVID-19Infections and infestations6/567/636/568/63
Urinary tract infectionInfections and infestations4/565/635/566/63
Psoriatic arthropathyMusculoskeletal and connective tissue disorders2/564/633/566/63
DiarrhoeaGastrointestinal disorders5/564/635/564/63
ArthralgiaMusculoskeletal and connective tissue disorders5/565/635/565/63
PsoriasisSkin and subcutaneous tissue disorders3/561/635/561/63
HypercholesterolaemiaMetabolism and nutrition disorders0/564/630/564/63
Respiratory tract infectionInfections and infestations3/561/633/561/63
Back painMusculoskeletal and connective tissue disorders3/563/633/563/63

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SecukinumabUstekinumabTotal
Mean54.4 ± 8.852.7 ± 12.753.5 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)SecukinumabUstekinumabTotal
Female394180
Male172239
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SecukinumabUstekinumabTotal
Caucasian5562117
Black101
Other011
08

Study locations

28 sites
  • Novartis Investigative Site
    Rendsburg, Schleswig-Holstein 24768, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Bad Bentheim, 48455, Germany
  • Novartis Investigative Site
    Bad Doberan, 18209, Germany
  • Novartis Investigative Site
    Berlin, 12435, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Cologne, 50937, Germany
  • Novartis Investigative Site
    Cologne, 51149, Germany
  • Novartis Investigative Site
    Cottbus, 03042, Germany
  • Novartis Investigative Site
    Dresden, 01067, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Ehringshausen, 35630, Germany
  • Novartis Investigative Site
    Erlangen, 91056, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Freiburg im Breisgau, 79106, Germany
  • Novartis Investigative Site
    Gommern, 39245, Germany
  • Novartis Investigative Site
    Göttingen, 37075, Germany
  • Novartis Investigative Site
    Hamburg, 22391, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Magdeburg, 39104, Germany
  • Novartis Investigative Site
    Magdeburg, 39110, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    München, 81541, Germany
  • Novartis Investigative Site
    Planegg, 82152, Germany
  • Novartis Investigative Site
    Ratingen, 40878, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Oct 2024, 46 months.

Results were first posted in Oct 2025, 11 months after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 46 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2020
First posted
Nov 17, 2020
StartActual
Dec 21, 2020
Primary completionActual
Oct 22, 2024
CompletionActual
Oct 22, 2024
Results first posted
Oct 16, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04632927
Responsible party
Sponsor
First posted
Nov 17, 2020
Start date
Dec 21, 2020
Primary completion
Oct 22, 2024
Completion
Oct 22, 2024
Results posted
Oct 16, 2025
Last update
Oct 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Secukinumab · Ustekinumab

Start the discussion